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Abstract
Background: Previous research has studied the rate of hepatitis C virus (HCV) coinfection among HIV-positive people regard-
less of their antiretroviral therapy (ART) status. Our objectives were to measure the seroprevalence of HCV both in HIV-positive
people receiving ART and in those not receiving ART and to describe the characteristics of coinfected people in the Kathmandu
Valley, Nepal. Methods: We conducted a cross-sectional survey of 319 HIV-positive people residing in the Kathmandu Valley,
Nepal. We screened the participants’ serum samples for HCV antibodies using the Latex Photometric Immunoassay based on
third-generation assay. Results: A total of 138 (43.3%) participants were HCV positive. The prevalence of HCV coinfection
was 96.2% (125 of 130) among participants with lifetime injection drug use (IDU). Among participants not receiving ART, the
coinfection rate was 58.1% (50 of 86) compared with 37.8% (88 of 233) among those receiving ART. In multivariable analysis,
participants who reported lifetime IDU and were current smokers were more likely to have HCV coinfection. The adjusted odds
ratio (AOR) of HCV coinfection for ART was decreased, although it was not statistically significant (AOR ¼ 0.45; 95% confidence
interval ¼ 0.13-1.48). Conclusion: The high prevalence of HCV coinfection among both individuals receiving ART and those
not receiving ART suggests that screening for HCV among HIV-positive people would be useful, in particular, for those with life-
time IDU and soon after their HIV diagnosis.
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Introduction
Coinfection of the hepatitis C virus (HCV) and HIV is an
important public health concern. Of the 33.4 million HIV-
positive people globally,1 around 20% are coinfected with
HCV.2 Coinfection of HCV and HIV accelerates liver disease
progression.3 Among coinfected patients, cirrhosis of the liver
is 6 times more likely compared with those infected solely with
HCV.4 The provision of antiretroviral therapy (ART) has dra-
matically increased the life span as well as the quality of life
for HIV-positive people both in developed and in resource-
limited countries. However, HCV-induced liver disease has
emerged as a major cause of morbidity and mortality, particu-
larly among HIV-positive people coinfected with HCV.3,5
The management of patients coinfected with HCV and HIV
is challenging. Coinfected patients are more likely to develop
liver enzyme abnormalities and liver toxicity when treated with
ART.3 The successful treatment of HCV has been associated
with a regression of liver fibrosis6,7 and with a reduced risk of
ART-related liver toxicity.8 HIV-positive people, therefore, are
encouraged to get screened for HCV, and those with positive
results are considered for HCV treatment. Knowing that patients
are coinfected informs practitioners to provide specific educa-
tion on HCV transmission and treatment, factors influencing
liver disease progression, risk reduction strategies, and risk of
reinfection.
Previous studies have assessed the prevalence of HCV
coinfection among HIV-positive people in resource-limited
countries, where the overall burden of coinfection is dispro-
portionately high.9-13 The rate of coinfection is highly vari-
able in these countries, ranging from 1.9% in South Africa14
and 2.4% in northern India15 to 36.2% in Brazil.9 In areas where
injection drug use (IDU) is a major route of HIV transmission,
coinfection rates of over 90% have been reported.11,15-17
Despite the high burden of coinfection, HCV screening is
not a routine practice among HIV-positive people particularly
among those who are not eligible for ART initiation, as is the
case in most resource-limited countries. The national guide-
lines of these countries recommend HCV screening before the
initiation of ART.18 However, the provision of ART is still
low in some resource-limited countries19 and is even worse
among IDUs.20 Late HIV diagnosis and delayed initiation of
ART are common in these countries, resulting in elevated
morbidity and mortality.21 Since HIV and HCV share a
common route of transmission, we assume that the rates of
coinfection are similarly high among those who have initiated
ART and those who have not. However, previous studies have
reported the rate of HCV coinfection among HIV-positive
people without regard for their ART status.9,10 Gaining
knowledge about HCV coinfection among HIV-positive peo-
ple, who have not yet initiated ART, would be useful to
inform the development of an HCV-screening strategy for this
group at high risk of liver disease.
We conducted this study in Nepal, a resource-limited coun-
try in South Asia. In Nepal, the first case of HIV/AIDS was
reported in 1988. Since then the HIV epidemic in the country
has advanced from ‘‘low prevalence’’ to a ‘‘concentrated epi-
demic,’’ with prevalence over 5% within a subgroup of most-
at-risk populations. In particular, HIV prevalence among IDUs
has remained high at 6.3% in 2011 in the Kathmandu Valley,
though declining gradually over the years. HIV prevalence
among IDUs in the Kathmandu Valley was 68% in 2003 and
20.7% in 2009.22
Similar to HIV, previous studies have reported high preva-
lence of HCV among IDUs in the Kathmandu Valley. In a
study in 1998,23 for example, the prevalence of anti-HCV was
94% among IDUs. In 2009, another study in the Kathmandu
Valley assessed the prevalence of anti-HCV among 118 IDUs
enrolled in opioid substitution therapy (OST) and 82 IDUs who
were not in the OST program. In that study, the prevalence of
anti-HCV among the OST users and nonusers was 80.5% and
57%, respectively.24 Hepatitis C virus is known to be more rap-
idly transmitted by IDU than HIV.25 This suggests that the pre-
valence of HCV coinfection should be high particularly among
HIV-positive people with lifetime IDU in the Kathmandu Val-
ley, regardless of their ART status. However, to date no studies
have been conducted to assess the rate of HCV coinfection
among HIV-positive people or the characteristics of coinfected
people in the Kathmandu Valley. National ART guidelines for
Nepal26 recommend screening for HCV among HIV-positive
people before ART initiation. However, specific guidelines are
still lacking for HCV screening among those HIV-positive peo-
ple who are not yet eligible for ART.
The objectives of this study were to measure the seropreva-
lence of HCV in HIV-positive people who are receiving ART
as well as those who are not receiving ART and to describe the
characteristics of coinfected people in the Kathmandu Valley,
Nepal.
Methods
Study Area
We conducted this cross-sectional study in the Kathmandu Val-
ley, Nepal, from February to March 2010 in the wider context
of a baseline survey of a prospective healthy living intervention
study headed by the first and the last authors.27-29 The Kath-
mandu Valley consists of 3 districts, namely Kathmandu, Lalit-
pur, and Bhaktapur, with an estimated population of 1.9 million
in 2006. In 2012, 6 of the 39 ART sites within the country were
located in the Kathmandu Valley.
Participants
We recruited a total of 322 participants for this study. The
inclusion criteria were age 18 years or older, self-reported diag-
nosis of HIV infection, currently living in the Kathmandu Val-
ley, and giving written informed consent to participate in the
study. We recruited the participants through the staff of 5 non-
governmental organizations working with HIV-positive people
in the Kathmandu Valley. The procedures of the study were
reviewed and approved by the ethical committees of the Nepal
Health Research Council, Kathmandu, Nepal; National Center
for Global Health and Medicine, Tokyo, Japan; and Waseda
University, Tokyo, Japan.
Procedures
We used a structured Nepali version of the questionnaire for
data collection. First, we developed the questionnaire in
English, translated it into the Nepali language, and then back
translated it into English. After the back translation, we revised
the Nepali version again. Finally, we pretested it with 30 HIV-
positive people and made additional modifications based on the
pretest results.
We hired 4 interviewers for the data collection. The first
author provided a day-long training session on the question-
naire and interview technique. The interviewers first informed
each of the participants individually about the study procedures
using an information sheet. The participants then signed the
informed consent form agreeing to participate in the study.
Subsequently, the interviewers conducted face-to-face inter-
views in a private setting using the structured questionnaire.
To enhance confidentiality, the interviewers reassured the
participants that codes would be used in all records instead
of their names or other identifying information. Each interview
took about 45 minutes. Participants were reimbursed 100 Nepali
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rupees (about US$1.35) for their transportation costs to and from
the interview venues.
Laboratory technicians hired for the study collected approx-
imately 10 mL of venous blood from each participant using an
evacuated tube. To separate the serum, the blood was centri-
fuged immediately at the interview site for 15 minutes. The
first and last authors supervised the fieldwork.
Measures
Measures included sociodemographic and health character-
istics, including age, sex, marital status, education, employ-
ment status, months since testing HIV positive, ART status,
hepatitis C status, and assessment of drug use, smoking, and
alcohol use.
We asked participants about their recent and lifetime use of
several substances including alcohol, marijuana, and others.
Alcohol use was assessed by asking participants whether they
had consumed any alcohol in the past 30 days. To assess life-
time IDU, we asked participants whether they had ever used
drugs by injection. In addition, we asked about IDU in the past
6 months. We assessed smoking status and categorized partici-
pants as current smokers if they reported smoking ‘‘every day’’
or ‘‘some days.’’30
We performed the anti-HCV test with the Latex Photometric
Immunoassay (LPIA) using test kits from Ortho HCV Abs
LPIA test III based on third-generation assay (Ortho-Clinical
Diagnostics, Tokyo, Japan).
Data Analysis
A total of 322 participants completed the structured
interview. However, 3 participants did not provide a blood
sample; thus, we included 319 participants in our analysis.
For the analysis, first, we calculated the frequencies and
descriptive statistics to summarize the general characteris-
tics of the participants. Second, we used the chi-square test
to assess the differences in sociodemographic and health
characteristics between participants who reported lifetime IDU
and those who did not and between participants who were
receiving ART and those who were not. Third, we examined
the bivariate associations between each independent variable
and HCV coinfection among the participants. Finally, we per-
formed multivariable logistic regression analysis to explore the
factors of HCV coinfection among the participants. We ana-
lyzed the data using SPSS version 15.0 (SPSS Inc, Chicago,
Illinois) for Windows.
Results
General Characteristics
The mean age of the participants was 35.6 years (SD ¼ 6.9
years). Of the total (n ¼ 319), 57.4% of participants were men,
68.7% were currently married, 31.7% were not employed,
73.1% were receiving ART, 40.8% reported lifetime IDU, and
8.5% (n¼ 27) reported IDU during the past 6 months (Table 1).
The median duration since testing HIV positive is 53 months.
Characteristics of the participants by IDU are shown in
Table 2. A higher proportion of male participants (68.3%)
reported lifetime IDU than female participants (3.7%). Simi-
larly, educational level of the participants, antiretroviral status,
current smoking status, alcohol use, and history of sexual inter-
course in the past 6 months were statistically associated with
lifetime drug use.
Characteristics of the participants by their ART status are
shown in Table 3. Fewer participants between 20 and 34 years
of age (65.4%) were receiving ART than those between 30 and
60 years of age (83.2%). Other characteristics of the partici-
pants that were statistically associated with their ART status
included sex, education level, lifetime drug use, current smok-
ing, and alcohol use. Of the 27 participants who had endorsed
IDU in the past 6 months, 15 were not receiving ART.
Table 1. Sociodemographic and Health Characteristics of the
Participants (n ¼ 319).
Characteristics n (%)
Age, y
20-34 182 (57.1)
35-60 137 (42.9)
Sex
Female 136 (42.6)
Male 183 (57.4)
Current marital status
Single 100 (31.3)
Married 219 (68.7)
Educationa
Never been to school 58 (18.3)
Primary level (1-5 years) 70 (22.1)
Above primary level 189 (59.6)
Employment
No 101 (31.7)
Business 65 (20.4)
Office employee 153 (47.9)
Months since testing HIV positive
1-25 81 (25.4)
26-52 77 (24.1)
53-85 81 (25.4)
86-258 80 (25.1)
On antiretroviral therapy
No 86 (26.9)
Yes 233 (73.1)
Lifetime injection drug use
Yes 130 (40.8)
No 189 (59.2)
Injection drug use in past 6 months
Yes 27 (8.5)
No 292 (91.5)
Current smoking
Yes 150 (47.0)
No 169 (53.0)
Alcohol use in the past month
Yes 40 (12.5)
No 279 (87.5)
a Two participants did not respond to this question.
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Prevalence of HCV Coinfection
A total of 138 (43.3%) participants were found to be HCV pos-
itive. The prevalence of HCV coinfection was 96.2% (125 of
130) among participants with lifetime IDU, while it was
6.9% among those without lifetime IDU. The prevalence of
HCV coinfection was 37.8% (88 of 233) among participants
receiving ART, while it was 58.1% (50 of 86) among those not
receiving ART. The prevalence of HCV coinfection was 93.3%
(14 of 15) among those participants who were not receiving
ART and had reported IDU in the past 6 months.
Factors Associated with HCV and HIV Coinfection
Factors associated with HCV coinfection among HIV-positive
participants in the bivariate analysis are shown in Table 4. In
the multivariable analysis, participants who reported lifetime
IDU were more likely to have HCV coinfection than those who
did not. Similarly, participants who were current smokers were
more likely to have HCV coinfection than those who were not.
The adjusted odds ratio (AOR) of HCV coinfection for ART
was decreased, although it was not statistically significant
(AOR ¼ 0.45; 95% confidence interval ¼ 0.13-1.48). Of the
13 participants who were coinfected with HCV but did not
report lifetime IDU, 8 reported having had sexual intercourse
in the past 6 months.
Discussion
This study revealed high prevalence of HCV coinfection among
HIV-positive people in the Kathmandu Valley, Nepal. Our data
indicate that more than 2 of 5 HIV-positive people had HCV
coinfection. The prevalence of coinfection was higher among
participants not receiving ART than those receiving ART though
the difference was not statistically significant in multivariable
analysis. Participants, who endorsed lifetime IDU and were
current smokers, were more likely to be coinfected with HCV.
A high proportion of HIV-positive people in this study were
coinfected with HCV. At 43.3%, the HCV coinfection rate in
our study far exceeded rates reported in India (2.4-3.5%)10,13
Table 2.Characteristics of the Participants by Their Lifetime Injection
Drug Use (n ¼ 319).
Characteristics
Lifetime History of IDU
P ValueYes, n (%) No, n (%)
Age, y
20-34 73 (40.1) 109 (59.9)
35-60 57 (41.6) 80 (58.4) .818
Sex
Female 5 (3.7) 131 (96.3)
Male 125 (68.3) 58 (31.7) <.001
Current marital status
Single 46 (46.9) 54 (54.0)
Married 84 (38.4) 135 (61.6) .220
Educationa
Up to primary 30 (23.4) 98 (76.6)
Secondary or above 99 (52.4) 90 (47.6) <.001
Employment
No 35 (34.7) 66 (65.3)
Yes 95 (43.6) 123 (56.4) .143
Months since testing HIV positive
1-52 56 (35.4) 102 (64.4)
53-258 74 (46.0) 87 (54.0) .068
On antiretroviral therapy
No 46 (53.5) 40 (46.5)
Yes 84 (36.1) 149 (63.9) .007
Current smoking
No 23 (13.6) 146 (86.4)
Yes 107 (71.3) 43 (28.7) <.001
Alcohol drinking
No 107 (38.4) 172 (61.6)
Yes 23 (57.5) 17 (42.5) .025
Had sex in the past 6 months
No 27 (29.0) 66 (71.0)
Yes 103 (45.6) 123 (54.4) .008
Abbreviation: IDU, injection drug user.
a Two participants did not respond to this question.
Table 3. Characteristics of the Participants by Their Antiretroviral
Therapy (n ¼ 319).
Characteristics
On Antiretroviral Therapy
P ValueYes, n (%) No, n (%)
Age, y
20-34 119 (65.4) 63 (35.6)
35-60 114 (83.2) 23 (16.8) <.001
Sex
Female 111 (81.6) 25 (18.4)
Male 122 (67.7) 61 (33.3) .003
Current marital status
Single 67 (67.0) 33 (33.0)
Married 166 (75.8) 53 (24.2) .105
Educationa
Up to primary 105 (82.0) 23 (18.0)
Secondary or above 126 (66.7) 63 (33.3) .003
Employment
No 72 (71.3) 29 (28.7)
Yes 171 (73.9) 57 (26.1) .684
Months since testing HIV positive
1-52 116 (73.4) 42 (26.6)
53-258 117 (72.7) 44 (27.3) .900
Lifetime injection drug use
No 149 (78.8) 40 (21.2)
Yes 83 (64.6) 46 (35.4) .007
Current smoking
No 137 (81.1) 32 (18.9)
Yes 96 (64.0) 54 (36.0) .001
Alcohol drinking
No 212 (76.0) 67 (24.0)
Yes 21 (52.5) 19 (47.5) .004
Had sex in the past 6 months
No 71 (76.3) 22 (23.7)
Yes 162 (71.7) 64 (28.3) .488
a Two participants did not respond to this question.
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and Brazil (36.2%).9 Over 40% of participants reported a life-
time history of IDU. The HCV coinfection in this study was
markedly associated with IDU similar to previous studies31,32;
almost all (96.2%) participants who reported the lifetime his-
tory of IDU were coinfected with HCV. According to previous
research, HCV is known to be more rapidly transmitted by IDU
than HIV.25
Similarly high levels of HCV coinfection among partici-
pants receiving ART and those not receiving ART have poten-
tial implications in designing HCV-screening strategies for
HIV-positive people and in counseling those with positive test
results. Rarely do either acute or chronic HCV present with sig-
nificant symptoms.33 Consequently, those infected are unlikely
to visit an HIV clinic or receive an HCV test without having
other medical problems. Infected people, who are not aware
of their HCV status, might unknowingly spread HCV to others.
In our study, for example, 15 participants who reported IDU in
the past 6 months were not receiving ART, and all except 1
were coinfected with HCV. These individuals could inadver-
tently transmit HCV to those with whom they share drug
paraphernalia.
In total, about 6 of the 10 participants, who were not receiv-
ing ART in our study, were coinfected with HCV. Without
innovative HCV-screening interventions, these participants are
unlikely to receive HCV testing until ART initiation. Although
HCV treatment is rare in Nepal26 like in many other resource-
limited countries,34 timely diagnosis of HCV would be benefi-
cial in order to educate patients regarding HCV transmission,
risk of reinfection, and liver disease progression.
HIV-positive current smokers in our study were more
likely to be coinfected with HCV than nonsmokers. The high
rate of smoking among HCV coinfected HIV-positive people
in our study is a cause for concern because smoking has been
identified as a risk factor for hepatocellular carcinoma.35,36
Moreover, a meta-analysis demonstrated evidence of a syner-
gistic effect between smoking and HCV infection on the risk
Table 4. Factors Associated with HCV Coinfection among HIV-Positive People in the Kathmandu Valley, Nepal.
Variables
HCV Coinfection
OR (95% CI) AORa (95% CI)Yes, n (%) No, n (%)
Age, y
20-34 76 (41.8) 106 (58.2)
35-60 62 (45.3) 75 (54.7) 1.15 (0.73-1.80) 1.37 (0.46-4.10)
Sex
Female 9 (6.6) 127 (93.4)
Male 129 (70.5) 54 (29.5) 33.71 (15.97-71.14) 2.93 (0.66-12.85)
Current marital status
Single 49 (49.0) 51 (51.0)
Married 89 (40.6) 130 (59.4) 0.71 (0.44-1.14) 0.64 (0.17-2.32)
Educationb
Up to primary 31 (24.2) 97 (75.8)
Secondary or above 106 (56.1) 83 (43.9) 3.99 (2.43-6.56) 2.85 (0.89-9.11)
Employment
No 35 (34.7) 66 (65.3)
Yes 103 (47.2) 115 (52.8) 1.68 (1.03-2.75) 2.36 (0.67-8.30)
Months since testing HIV positive
1-52 58 (36.7) 100 (63.3)
53-258 80 (49.7) 81 (50.3) 1.70 (1.08-2.66) 1.39 (0.47-4.09)
On antiretroviral therapy
No 50 (58.1) 36 (41.9)
Yes 88 (37.8) 145 (62.2) 0.43 (0.26-0.72) 0.45 (0.13-1.48)
Lifetime injection drug use
No 13 (6.9) 176 (93.1)
Yes 125 (96.2) 5 (3.8) 338.46 (117.66-973.58) 169.60 (47.50-605.60)
Current smoking
No 27 (16.0) 142 (84.0)
Yes 111 (74.0) 39 (26.0) 14.96 (8.63-25.94) 3.58 (1.12-11.44)
Alcohol drinking
No 115 (41.2) 164 (58.8)
Yes 23 (57.5) 17 (42.5) 1.92 (0.98-3.77) 0.57 (0.11-3.03)
Had sex in the past 6 months
No 31 (33.3) 62 (66.7)
Yes 107 (47.3) 119 (52.7) 1.79 (1.08-2.97) 0.46 (0.10-1.99)
Abbreviations: OR, odds ratio; CI, confidence interval; AOR, adjusted odds ratio; HCV, hepatitis C virus.
a A total of 317 participants were included in the multiple logistic regression analysis (R2 ¼ 85.2).
b Two participants did not respond to this question.
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of hepatocellular carcinoma.37 It is, therefore, important to en-
courage HCV-coinfected HIV-positive people to quit smoking.
An important question is how participants, who denied life-
time IDU, contracted HCV. In our study, a total of 13 HCV-
coinfected HIV-positive participants did not report lifetime
IDU. Eight of these participants had had sexual intercourse in
the past 6 months. Although sexual transmission of HCV is still
controversial, traumatic intercourse may lead to a loss of muco-
sal barriers and may facilitate the sexual transmission of
HCV.38,39 Unfortunately, we did not measure lifetime sexual
behaviors and other important information, such as the history
of sharing razors or toothbrushes, blood transfusion, dialysis,
tattoo, and other potential modes of transmission. Further stud-
ies would be needed to address this issue.
Our study has 2 limitations. First, the diagnosis of HCV in
our study was based on anti-HCV antibody testing; HCV RNA
analysis was not performed to confirm the diagnosis. However,
it is likely that the HCV prevalence will remain high and that
the characteristics of the coinfected people will remain similar
even after confirmation of the diagnosis. This is because HCV
and HIV coinfection is associated with a reduced rate of spon-
taneous clearance of HCV RNA, with over 80% of patients
developing chronic infection.40 Next, as we relied on self-
reported data, the responses of our participants might have been
influenced by social desirability bias, although our methodol-
ogy attempted to minimize this effect.
Despite these limitations, our study documented high preva-
lence of HCV coinfection both among HIV-positive people
receiving ART and those not receiving ART in the Kathmandu
Valley, Nepal. It is likely that IDU was the major route of HCV
transmission among our study participants. Screening for HCV
among HIV-positive people, particularly those with lifetime
IDU and soon after their HIV diagnosis, would be useful for the
timely identification of HCV coinfection as well as education
and possibly treatment.
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